Summary by Futu AI
Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have jointly filed a Schedule 13G with the SEC, disclosing a 0.9% ownership stake in Transcode Therapeutics, Inc. as of December 31, 2024. The group collectively holds 69,555 shares of the company's common stock.The filing indicates shared voting and dispositive power over all 69,555 shares among the reporting persons. Sabby Management, LLC is based in Florida, while Sabby Volatility Warrant Master Fund Ltd is incorporated in the Cayman Islands. Hal Mintz, associated with Sabby Management, is a U.S. citizen.The reporting persons certified that the securities were not acquired to change or influence control of Transcode Therapeutics. This Schedule 13G was signed on January 3, 2025, by Robert Grundstein, COO of Sabby Management, and Hal Mintz.
Comment(0)
Reason For Report